Last reviewed · How we verify

NCT04375735: LESSCOVID

London's Exogenous Surfactant Study for COVID19

Completed Phase 1, PHASE2 Last updated 11 November 2021
What this trial tests

Phase 1, PHASE2 trial testing Bovine Lipid Extract Surfactant in ARDS, Human in 20 participants. Completed in 6 October 2021.

Timeline
23 November 2020
Primary endpoint
1 September 2021
6 October 2021

Quick facts

Lead sponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment20
Start date23 November 2020
Primary completion1 September 2021
Estimated completion6 October 2021
Sites2 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Who can join

18 and older, any sex, with ARDS, Human or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The research team is investigating administering exogenous surfactant in COVID-19 patients with ARDS. The overall goal is to improve the outcome (mortality) of mechanically ventilated COVID-19 patients. Although the investigators anticipate that clinical outcomes may improve in the small group of patients receiving exogenous surfactant therapy in this small, single center study, the primary goal is to first determine feasibility and safety.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation.
    Aboudounya MM, Heads RJ. · · 2021 · cited 267× · PMID 33505220 · DOI 10.1155/2021/8874339
  2. The Role of Pulmonary Surfactants in the Treatment of Acute Respiratory Distress Syndrome in COVID-19.
    Wang S, Li Z, Wang X, Zhang S, et al · · 2021 · cited 36× · PMID 34267664 · DOI 10.3389/fphar.2021.698905
  3. Alveolar type II cells and pulmonary surfactant in COVID-19 era.
    Calkovska A, Kolomaznik M, Calkovsky V. · · 2021 · cited 31× · PMID 34913352 · DOI 10.33549/physiolres.934763
  4. Assessment of pulmonary surfactant in COVID-19 patients.
    Schousboe P, Wiese L, Heiring C, Verder H, et al · · 2020 · cited 27× · PMID 32894160 · DOI 10.1186/s13054-020-03268-9
  5. Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia.
    Busani S, Dall'Ara L, Tonelli R, Clini E, et al · · 2020 · cited 21× · PMID 32865137 · DOI 10.1177/1753466620951043
  6. Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review.
    Matera MG, Rogliani P, Calzetta L, Cazzola M. · · 2020 · cited 21× · PMID 32795902 · DOI 10.1016/j.rmed.2020.106114
  7. A therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response.
    Leibel SL, McVicar RN, Murad R, Kwong EM, et al · · 2024 · cited 8× · PMID 39028694 · DOI 10.1073/pnas.2408109121
  8. Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components.
    Li D, Wang X, Liao Y, Wang S, et al · · 2022 · cited 6× · PMID 35592339 · DOI 10.3389/fimmu.2022.842453

Verify or expand the search:

Other recruiting trials for ARDS, Human

Currently open trials in the same condition.

Other London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04375735.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing